Novel proteasome inhibitors

Advances in Biology and Therapy of Multiple Myeloma: Volume 2: Translational and Clinical Research

Volumn , Issue , 2013, Pages 157-180

  Orlowski, Robert Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84948164402     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5260-7_7     Document Type: Chapter

References (78)

1. Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20 (22):4420-7
2. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (26):2609-17
3. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexametha-sone for relapsed multiple myeloma. N Engl J Med 352 (24):2487-98
4. Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol25 (25):3892-901
5. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 (9):906-17
6. Rock KL, Gramm C, Rothstein L et al (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-71
7. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 (6):1649-57
8. Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23 (11):1964-79
9. Dick LR, Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15 (5-6):243-249
10. Adams J, Behnke M, Chen S et al (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8 (4):333-8
11. Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59 (11):2615-22
12. Hanada M, Sugawara K, Kaneta K et al (1992) Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 45 (11):1746-1752
13. Sin N, Kim KB, Elofsson M et al (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett9:2283-2288
14. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96 (18):10403-10408
15. Kim KB, Myung J, Sin N, Crews CM (1999) Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett 9 (23):3335-3340
16. Kuhn DJ, Chen Q, Voorhees PM et al (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110 (9):3281-3290
17. Demo SD, Kirk CJ, Aujay MA et al (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67 (13):6383-6391
18. Parlati F, Lee SJ, Aujay M et al (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114 (16):3439-47
19. Paoluzzi L, Gonen M, Bhagat G et al (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112 (7): 2906-16
20. Paoluzzi L, Gonen M, Gardner JR et al (2008) Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111 (11):5350-8
21. Dasmahapatra G, Lembersky D, Kramer L et al (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115 (22):4478-87
22. DiLiberto M, Huang X, Zewdu R et al (2009) Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfil zomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim. Blood (ASH Annual Meeting Abstract) 114:2854
23. Huang X, Di Liberto M, Ely S et al (2009) Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4. Blood (ASH Annual Meeting Abstract) 114:299
24. O’Connor OA, Stewart AK, Vallone M et al (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15 (22):7085-91
25. Arastu-Kapur S, Shenk K, Parlati F, Bennett MK (2008) Non-proteasomal targets of protea-some inhibitors bortezomib and carfilzomib. Blood (ASH Annual Meeting Abstract)112:2657
26. Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A (2007) Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstract)110:411
27. Jagannath S, Vij R, Stewart K et al (2009) Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol 27(15s), ASCO Annual Meeting Abstract 8504
28. Jagannath S, Vij R, Stewart K et al (2009) Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol 27(15s), ASCO Annual Meeting Abstract. http://www.onyx-pharm.com/view.cfm/690/Onyx-Pharmaceuticals-Announces-Positive-Top-Line-Carfilzomib-Data-from-Phase-2b-Study; 2010.
29. Siegel D, Wang L, Orlowski RZ et al (2009) PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood (ASH Annual Meeting Abstract)114:303
30. Wang L, Siegel D, Kaufman JL et al (2009) Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). Blood (ASH Annual Meeting Abstract)114:302
31. Richardson PG, Weller E, Jagannath S et al (2009) Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 27 (34):5713-5719
32. Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexametha-sone combination therapy in patients with newly diagnosed multiple myeloma. Blood116 (5):679-86
33. Bensinger W, Wang M, Orlowski RZ et al (2010) Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM). J Clin Oncol 28(15s), ASCO Annual Meeting Abstract 8029
34. Muchamuel T, Aujay M, Bennett MK et al (2008) Preclinical pharmacology and in vitro characterization of PR-047, an oral inhibitor of the 20S proteasome. Blood (ASH Annual Meeting Abstract) 112:3671
35. Zhou HJ, Aujay MA, Bennett MK et al (2009) Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 52 (9):3028-38
36. Muchamuel T, Kapur S, Kirk CJ et al (2009) Dose intensive administration of PR-047, a novel orally bioavailable inhibitor of the 20S proteasome, is well tolerated in experimental animals. Blood (ASH Annual Meeting Abstract) 114:4910
37. Roccaro AM, Sacco A, Aujay M et al (2010) Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 115 (20):4051-60
38. Huang X, Bailey K, Di Liberto M et al (2008) Induction of sustained early G1 arrest by selective inhibition of CDK4 and CDK6 primes myeloma cells for synergistic killing by protea-some inhibitors carfilzomib and PR-047. Blood (ASH Annual Meeting Abstract) 112:3670
39. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W (2003)Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42 (3):355-7
40. Fenteany G, Schreiber SL (1998) Lactacystin, proteasome function, and cell fate. J Biol Chem273 (15):8545-8
41. Ling T, Potts BC, Macherla VR (2010) Concise formal synthesis of (-)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy. J Org Chem 75 (11):3882-5
42. Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell8(5):407-19
43. Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC (2010)Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (mari-zomib) in a human plasmacytoma xenograft murine model. Br J Haematol 149 (4):550-9
44. Ahn KS, Sethi G, Chao TH et al (2007) Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood 110 (7):2286-95
45. Chauhan D, Singh A, Brahmandam M et al (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111 (3): 1654-1664
46. Roccaro AM, Leleu X, Sacco A et al (2008) Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 111 (9):4752-63
47. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC (2010)Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115 (4):834-45
48. Huang X, Louie T, Di Liberto M et al (2007) Targeting cdk4/6 in combination therapy overcomes proteasome inhibitor resistance in multiple myeloma through synergistic mitochondria depolarization. Blood (ASH Annual Meeting Abstracts) 110:667
49. Kurzrock R, Hamlin P, Younes A et al (2007) Phase 1 clinical trial of a novel proteasome inhibitor (NPI-0052) in patients with lymphomas and solid tumors. Blood (ASH Annual Meeting Abstract) 110:4504
50. Hamlin PA, Aghajanian C, Hong D et al (2008) First-in-human phase 1 dose escalation study of NPI-0052, a novel proteasome inhibitor, in patients with lymphoma and solid tumor. Blood (ASH Annual Meeting Abstracts) 112:4939
51. Hamlin PA, Aghajanian C, Younes A et al (2009) First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052. J Clin Oncol 27(15s):3516, ASCO Annual Meeting Abstract
52. Price T, Padrik P, Townsend A et al (2008) Clinical trial of NPI-0052 (2nd generation proteasome inhibitor) in patients having advanced malignancies with expanded RP2D cohorts in lymphoma and CLL. Blood 112:4934, ASH Annual Meeting Abstract
53. Townsend AR, Millward M, Price T et al (2009) Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol 27(15s):3582, ASCO Annual Meeting Abstract
54. Spencer A, Millward M, Mainwaring P et al (2009) Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052. Blood 114:2693, ASH Annual Meeting Abstract
55. Richardson P, Hofmeister C, Jakubowiak A et al (2009) Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstract) 114:431
56. Dorsey BD, Iqbal M, Chatteijee S et al (2008) Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 51 (4):1068-72
57. Piva R, Ruggeri B, Williams M et al (2008) CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood111 (5):2765-75
58. Trippier PC, McGuigan C, Balzarini J (2010) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: monophenylboronic acids. Antivir Chem Chemother 20 (6):249-57
59. Sanchez E, Li M, Steinberg JA et al (2010) The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 148 (4):569-81
60. Marangon E, Sala F, Sessa C, et al. Pharmacokinetics and pharmacodynamics of the new proteasome inhibitor CEP-18770 Preliminary results from a phase I study. J Am Soc Mass Spectrom 2009;20(5, Supplement 1):Annual ASMS Meeting Abstract 452
61. Kupperman E, Lee EC, Cao Y et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70 (5):1970-80
62. Donelan J, Bannerman B, Bano K et al (2009) Antitumor activity of MLN9708, a second-generation proteasome inhibitor, in preclinical models of lymphoma. Blood 114:3724, ASH Annual Meeting Abstract
63. Lee E, Bannerman B, Fitzgerald M et al (2009) MLN9708 elicits pharmacodynamic response in the bone marrow compartment and has strong antitumor activity in a preclinical intraosseous model of plasma cell malignancy. Blood 114:1834, ASH Annual Meeting Abstract
64. Fitzgerald M, Cao Y, Bannerman B et al (2009) Evaluating the antitumor activity of MLN9708 in a disseminated mouse model of double transgenic iMyc Ca/Bcl-XL plasma cell malignancy. Blood 114:3835, ASH Annual Meeting Abstract
65. Janz S, Van Ness BG, Neppalli V et al (2009) The novel proteasome inhibitor MLN9708 demonstrates efficacy in a genetically-engineered mouse model of denovo plasma cell malignancy. Blood 114:3849, ASH Annual Meeting Abstract
66. Rodler ET, Infante JR, Siu LL et al (2010) First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. J Clin Oncol 28:3071, ASCO Annual Meeting Abstract
67. Kloetzel PM, Ossendorp F (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16 (1):76-81
68. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ (2009) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood113 (19):4667-4676
69. Muchamuel T, Basler M, Aujay MA et al (2009) A selective inhibitor of the immunoprotea-some subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15(7):781-787
70. Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res9 (13):4653-65
71. Yasui H, Hideshima T, Richardson PG, Anderson KC (2006) Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 132 (4): 385-97
72. Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 110 (9):1911-28
73. Voorhees PM, Chen Q, Kuhn DJ et al (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 13 (21):6469-78
74. Voorhees PM, Chen Q, Small GW et al (2009) Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145 (4):481-90
75. Singh AV, Bandi M, Aujay M et al (2009) PR-924, a selective inhibitor of the immunoprotea-some subunit LMP-7 blocks multiple myeloma cell growth both in vitro and In vivo. Blood 114:612, ASH Annual Meeting Abstract
76. Jagannath S, Barlogie B, Berenson JR et al (2005) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer103 (6): 1195-200
77. Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109 (6):2604-2606
78. Blade J, Sonneveld P, SanMiguel F et al (2008) Pegylated liposomal doxorubicin plus borte-zomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8 (6):352-355